Alnylam, based in Cambridge, MA, has led the translation of RNAi from Nobel Prize-winning discovery into an entirely new class of medicines. In 2018, their first medicine, ONPATTRO (patisiran), became the world’s first approved RNAi therapeutic. Their second medicine, GIVLAARI (givosiran), was approved in 2019, followed closely by OXLUMO (lumasiran), cleared in 2020. They are advancing a robust pipeline of innovative RNAi-based medicines in four therapeutic areas: genetic medicines, cardio-metabolic diseases, infectious diseases, and CNS and ocular diseases. Join us to learn how Alnylam conceives and develops therapies in this exciting new area.
Where & When
Zoom Webinar
1:00 to 2:00 PM PT, Wednesday, November 3, 2021
About the Speaker
Dr. Vasant Jadhav is Senior VP, Research at Alnylam Pharmaceuticals. He has over 20 years of experience in the chemical biology research of nucleic acids spanning academic, biotech and big pharma industry for basic, diagnostic and therapeutic applications. He has a proven record of delivering insightful breakthroughs as an individual contributor and then growing in the role of team leader overseeing several large multi-disciplinary teams in highly collaborative and timely manner to deliver on the objectives.
Dr. Jadhav optimized fully modified siRNA technology and conceived novel siRNA designs, both key assets of Sirna Therapeutics. In addition, he managed collaborations with GSK and Allergan as a scientific lead in the field of respiratory and ocular diseases respectively.
He initiated, established and oversaw biology efforts of Merck’s industry leading siRNA conjugate delivery platform. He led comprehensive efforts to engage internal and external scientific experts to unearth novel ways of enhancing cytosolic release of siRNA- the biggest barrier to fully realize potential of siRNA.
Dr. Jadhav earned his PhD from the National Chemical Laboratory in Pune, India, and completed a postdoctoral fellowship at the University of Colorado, Boulder.